Table 3 Correlation between exosomes level, KRAS copies and clinical-pathological characteristics in metastatic CRC patients.

From: Mutational status of plasma exosomal KRAS predicts outcome in patients with metastatic colorectal cancer

Level (µg/ml)

Number of lesions

P-value

Single lesion

Multiple lesions

Basal

142.3 ± 190.4

382.7 ± 479.4

0.046

Post-therapy

133.6 ± 189.9

266.4 ± 314.9

0.99

Progression

309.1 ± 545.0

680.0 ± 744.0

0.037

KRAS WT copies

KRAS mutational status

P-value

KRAS G12V

KRAS G12D

WT

Basal

287.3 ± 268.9*

176.0 ± 124.7*

179.3 ± 216.4*

0.001

Post-therapy

134.2 ± 152.7

84.4 ± 41.9

140.0 ± 136.7

0.749

Progression

257.8 ± 159.05*

214.6 ± 163.8

119.8 ± 115.6*

0.003

KRAS WT copies

KRAS mutational status

p-value

KRAS G12V

WT

Basal

241.3 ± 208.7

170.3 ± 150.0

0.011

Post-therapy

175.0 ± 129.5

106.7 ± 116.3

0.645

Progression

245.3 ± 156.0

114.0 ± 114.6

0.001

KRAS WT copies

Liver metastases

p-value

Yes

No

Basal

227.1 ± 228.6

170.3 ± 150.0

0.146

Post-therapy

175.0 ± 129.5

106.7 ± 116.3

0.803

Progression

245.3 ± 156.0

114.0 ± 114.6

0.009

KRAS G12D/V copies

Liver metastases

p-value

Yes

No

Basal

51.04 ± 109.3

6.0 ± 11.9

0.015

Post-therapy

2.1 ± 6.6

8.0 ± 16.0

0.627

Progression

43.6 ± 60.8

8.6 ± 17.7

0.067

Fractional abundance (%)

Liver metastases

p-value

Yes

No

Basal

15.7 ± 18.3

2.5 ± 8.1

0.020

Post-therapy

1.38 ± 4.5

0 ± 0

0.787

Progression

16.4 ± 16.8

2.1 ± 6.1

0.030

KRAS G12/V copies

CEA

P-value

Low

High

Basal

17.1 ± 24.53

59.6 ± 126.3

0.163

Post-surgery

5.0 ± 11.3

1.53 ± 5.5

0.649

Progression

16.1 ± 28.0

51.4 ± 66.9

0.024

Fractional abundance (%)

CEA

P-value

Low

High

Basal

6.4 ± 11.3

17.3 ± 19.2

0.077

Post-surgery

2.01 ± 6.0

0.62 ± 2.2

0.896

Progression

5.8 ± 10.3

18.3 ± 17.7

0.022

Back to article page